Global Cell Line Development Market - Key Drivers and Forecast from Technavio

Technavio has published a new report on the global cell line development market from 2017-2021. (Graphic: Business Wire)

LONDON--()--Technavio analysts forecast the global cell line development market to grow at a CAGR of more than 12% over the forecast period, according to their latest report.

The research study by Technavio on the global cell line development market for 2017-2021 provides a detailed industry analysis based on the product (product type, media and reagent, and equipment) and geography (the Americas, EMEA, and APAC).

The cell line development market is rising owing to factors such as an increasing importance of life science. With the increasing replacement of animal studies by cell- and tissue-based assays, there has been an increase in reliance on cells to demonstrate greater biological relevance among researchers. Also, with the help of therapeutic technology, it is now possible to improve the performance of the production cells with respect to productivity and product quality.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio analysts highlight the following three factors that are contributing to the growth of the global cell line development market:

  • Increased demand for monoclonal antibodies
  • Patent expiration of drugs
  • Rise in vaccine production

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Increased demand for monoclonal antibodies

A monoclonal antibody is a type of protein which is developed in the laboratory for binding to substances in the body such as cancer cells. It binds to only one kind of substance, so at present, there are many kinds of monoclonal antibodies, which are used as therapeutic agents such as treatment of different types of cancer,” explains Amber Chourasia, a lead analyst at Technavio for lab equipment research.

Monoclonal antibodies (mAbs) are either used alone or in conjugation with drugs, radioactive substances or toxins to kill the diseased cells. mAbs are being used in immunotherapy where they bind to certain cells like T-cells to stimulate the patient’s immune system to attack antigens such as pathogens and virus. These mAbs are produced through cell line, thus benefitting the market.

Patent expiration of drugs

Currently, many global pharmaceutical companies are facing various patent expirations on big selling products, and many more are going to expire over the forecast period. The expiry of these patents will result in the mass production of generic drugs and biosimilars, which are chemically identical to a brand name drug in terms of dosage, strength, safety, route of administration. These generic drugs are sold at discount price as compared to branded price because of cost effective R&D.

In 2017, approximately 20 drugs will go off-patent, which provides an opportunity to alternative generic and biosimilar products to enter the market, which is manufactured by competitor vendors. Since cell line is used in the production of biosimilars and there is an increasing demand for biosimilars, the demand for cell line development will also increase.

Rise in vaccine production

Vaccines are one of the cost-effective and successful strategies for precaution against common diseases. At present, around 15%-20% of infants are still unimmunized, which results in a need for raising awareness along with increasing investments by companies. Also, the rise in an outbreak of diseases has resulted in an increase in the production of vaccines.

Vaccines are majorly produced by utilizing cell lines as they can produce vaccines rapidly during an impending pandemic. Also, synthetic media can be used for cell line proliferation, which prevents the spread of transmissible spongiform encephalopathies by avoiding animal serum as growth media,” says Amber.

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770

Release Summary

Technavio analysts forecast the global cell line development market to grow at a CAGR of over 12% during the forecast period, 2017-2021.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770